Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMO study: ranibizumab for refractory uveitic cystoid macular oedema
2011-001869-41Phase 2Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Jul 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in uveitic macular edema (UME) and uveitis, sponsored by Moorfields Eye Hospital. Primary endpoint: Need for further treatment. Started Jul 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
uveitic macular edema (UME)uveitis
Beyond the preview
Go deeper on 2011-001869-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001869-41.